Prolonged PR interval, first-degree heart block and adverse cardiovascular outcomes: a systematic review and meta-analysis by Kwok, Chun Shing et al.
Prolonged PR interval, first-degree heart block and adverse cardiovascular outcomes: 
A systematic review and meta-analysis 
Chun Shing Kwok1, Muhammad Rashid2, Diane Barker3, Rhys Beynon3, Ashish Patwala3, 
Adrian Morley-Davies3, Duwarakan Satchithananda3, Yoon K Loke4, Mamas Mamas1, 3 
1. Keele Cardiovascular Research Group, Institutes of Science and Technology in Medicine 
and Primary Care and Health Sciences, UK. 
2. St. Helens & Knowsley Teaching Hospital (NHS) Trust, Whiston Hospital, Prescot, UK. 
3. University Hospital of North Midland NHS Trust, Royal Stoke University Hospital, Stoke 
on Trent, UK. 
4. Norwich Medical School, University of East Anglia, Norwich, UK. 
Corresponding Author:  
Dr. Chun Shing Kwok 
Academic Clinical Fellow in Cardiology 
Keele Cardiovascular Research Group, 
University of Keele 
Stoke-on-Trent, United Kingdom 
Email: shingkwok@doctors.org.uk 
Telephone: +44 (0) 
Fax: +44 (0)178 2674467 
 
Abstract 
Background: First-degree heart block is generally considered a benign condition but 
emerging evidence suggests that it may be associated with adverse outcomes. 
Methods:  We searched MEDLINE and EMBASE for comparative studies that evaluated 
clinical outcomes associated with prolonged and normal PR intervals in general populations 
or those with cardiovascular risk factors or stable coronary disease.  Relevant studies were 
pooled using random effects meta-analysis for risk of mortality, cardiovascular mortality, 
heart failure, coronary heart disease, atrial fibrillation and stroke or TIA.  Sensitivity analyses 
were performed considering the population type and use of adjustments. 
Results:  Our search yielded 14 studies that were undertaken between 1972 and 2011 with 
400,750 participants.  Among the studies that adjusted for potential confounders, the pooled 
results suggest an increased risk of mortality with prolonged PR interval RR 1.24 95%CI 
1.02-1.51.   Prolonged PR interval was associated with significant risk of heart failure or left 
ventricular dysfunction (RR 1.39 95%CI 1.18-1.65) and atrial fibrillation (RR 1.45 95%CI 
1.23-1.71) but not cardiovascular mortality, coronary heart disease or myocardial infarction 
or stroke or TIA.  Similar significant increases in mortality, heart failure and atrial fibrillation 
were observed when limited to studies of first-degree heart block.   
Conclusions:  Data from observational studies indicates that prolonged PR interval and first-
degree heart block is associated with significant increases in atrial fibrillation, heart failure 
and mortality.  Future studies should focus on providing mechanistic insight and define the 
optimal monitoring strategy for such patients.
Introduction 
 First-degree atrioventricular block (1°HB), defined as PR interval greater than 200 
ms, is frequently encountered in clinical practice and considered a benign process.[1,2]  The 
PR interval measure reflects the propagation of electrical activity from the sinus node to the 
atrioventricular node. Although the prevalence of PR prolongation is relatively rare amongst 
the younger population (1% among those age <60) it becomes much more common after the 
age ≥60 years, with prevalence rising to 6% .[3]  However, there is a group within the young 
population who are trained athletes that having much higher rates of 1°HB due to slow 
atrioventricular conduction secondary to increase parasympathetic tone and decreased 
sympathetic tone.[4,5]  It has been suggested that enhanced vagal tone is the aetiology of 
1°HB in young people while for older subjects organic heart disease is more prevalent and 
may be linked to myocardial conduction system fibrosis.[6] In patients who are incidentally 
found to have 1°HB , current expert advice suggests that 1°HB poses little risk, is not 
associated with significant symptoms, and no specific treatment is required.( 
http://www.nhs.uk/Conditions/Heart-block/Pages/Introduction.aspx; 
http://my.clevelandclinic.org/services/heart/disorders/arrhythmia/heart-block 
http://www.merckmanuals.com/professional/cardiovascular-disorders/arrhythmias-and-
conduction-disorders/atrioventricular-block 
 The European Society of Cardiology recommends with class IIa and level C evidence 
that permanent pacemaker should be considered for patients with persistent symptoms similar 
to those of pacemaker syndrome and attributable to 1°HB (PR >0.3s).[7]   The 
ACC/AHA/HRS 2008 guides suggest that permanent pacemaker is not indicated for 
asymptomatic 1°HB except for neuromuscular disease such as myotonic dystrophy.[8] 
However, there is emerging evidence that it may be associated with increased risk of atrial 
fibrillation, pacemaker insertion and mortality.[9] 
 However, the current conservative approach to 1°HB may have been developed based 
on older studies with major methodological limitations.(ref: Erikssen, Rajala) Judgements 
regarding the benign nature of 1°HB and prolonged PR interval may be erroneous because of 
small sample sizes, inadequate follow up to capture sufficient events, confounding, lack of 
adjustments for baseline characteristics or poor outcome ascertainment. Several more recent 
studies have drawn association between prolonged PR interval and cardiovascular outcomes 
but there are clearly conflicting  viewpoints in the existing literature.[9-14]  The only 
previous systematic review evaluated the risk of atrial fibrillation with prolonged PR interval 
but this review did not look at other outcomes as mortality and cardiovascular diseases.[15]  
As there are several recent publications, we feel it is very important to re-assess this 
relationship.  The clinical importance is that we do not want to simply dismiss a potential 
adverse association, and falsely reassure patients that they will not come to any serious harm. 
 We conducted a systematic review and meta-analysis to evaluate the association 
between prolonged PR interval or 1°HB and mortality, atrial fibrillation, heart failure, 
coronary heart disease and stroke. 
Methods 
Eligibility criteria 
We selected studies that evaluated adverse outcomes in patients with and without 
1°HB or prolonged PR interval on electrocardiogram.  The adverse outcomes of interest were 
mortality, cardiovascular mortality, heart failure or left ventricular dysfunction, coronary 
heart disease or myocardial infarction, atrial fibrillation, stroke or transient ischemic attack, 
progression of heart block or need for pacemaker insertion.  While 1°HB was clearly defined 
as > or ≥ 200 ms, there was no specific choice of cutoff for prolonged PR interval as long as 
the PR interval was ≥200 ms.  Included studies had to have two groups (one with longer PR 
interval) which would allow risk estimates to be calculated.  There was no restriction based 
on study design, cohort type or language of study report.  However, we excluded studies of 
patients with specific cardiac pathologies that were uncommon such as (aortic stenosis, sinus 
nodal dysfunction, heart failure) or had received intervention (angiography or cardiac 
resynchronization therapy) from the main analysis. 
Search strategy 
 We searched MEDLINE and EMBASE using OVID SP with no date or language 
restriction in May 2015.  The exact search terms were: (first degree atrioventricular heart 
block or prolonged PR interval or PR prolongation or first-degree atrioventricular block) 
AND (atrial fibrillation or myocardial infarction or acute coronary syndrome or ischemic 
heart disease or ischaemic heart disease or coronary heart disease or coronary artery disease 
or stroke or cerebrovascular disease or cerebrovascular accident or heart failure or cardiac 
failure or mortality or death).  We checked the bibliography of relevant studies and reviews 
for additional studies that met the inclusion criteria. 
Study selection and data extraction 
 Two reviewers (CSK, MR) screened all titles and abstracts retrieved from the search 
for studies that met the inclusion criteria.  The full manuscript of studies that potentially met 
the inclusion criteria were reviewed and the final decision to include or exclude studies were 
made with two other reviewers (YKL, MAM).  Independent double extractions were 
performed by two reviewers (CSK, MR) and data was collected on study design, year, 
country, number of participants, mean age, % male, participant inclusion criteria, definition 
of prolonged PR interval, outcomes evaluated, timing of assessment and results.  
Risk of bias assessment 
Quality assessment of the studies were conducted with consideration of ascertainment 
of PR prolongation, outcome ascertainment, lost to follow up and use of adjustments for 
medication, cardiovascular disease and other adjustments. We aimed to contact authors to 
clarify any uncertainties in reported data.  Publication bias was considered using asymmetry 
testing if there were more than 10 studies in the meta-analysis, and if there was statistical 
heterogeneity <50%.[16] 
Data analysis 
 We used RevMan 5.3.5 (Nordic Cochrane Centre) to conduct random effects meta-
analysis using the inverse variance method for pooling risk ratios (RR).  Where possible, we 
shoes to pool adjusted risk estimates from primary studies and when this data was not 
available raw data was used to calculate unadjusted risk estimates.  The primary outcome was 
all-cause mortality and analysis was performed considering adjusted and unadjusted group 
separately.  Subgroup analysis was performed considering whether the population evaluated 
was a general population of subjects with cardiovascular disease.  We also performed 
sensitivity analysis by including only studies which evaluated 1°HB (>200ms or ≥200 ms) 
excluding studies which did not adjust for a) medications and b) cardiovascular disease. 
Results 
Description of studies included in analysis 
 The progress of study selection is shown in Figure 1. Out of the 879 studies retrieved 
from the search, 23 studies were relevant but 9 studies were excluded from the analysis 
(Appendix 1).  A total of 14 studies[6,9-14,17-23] were included: 12 general population 
studies, 1 coronary heart disease cohorts[17] and 1 hypertensive cohort.[13] 
 Table 1 shows the baseline characteristics of the participants.  There were a total of 
400,750 participants among the 14 studies (11 prospective cohort studies,[6,9,10,14,17-23] 3 
retrospective cohort studies[11-13]).  The mean age from 10 studies is 56 years and 62% 
were male.  The studies were undertaken between 1972 and 2011 and they took place in 
Finland, USA, Norway, Japan, Korea, Australia and Denmark.  Prevalence of prolonged PR 
interval ranged from 2% to 14% across 7 studies and the mean prevalence was 7%.  
 The evaluation of the quality of studies is shown in Table 2.  All studies used ECG to 
ascertain PR prolongation but only eight studies reported the leads used to measure PR 
interval.  A variety of methods were used to ascertain outcomes including data from 
registries, telephone contact and medical records.  Seven studies reported some degree of lost 
to follow up.  Aside for two studies, all the studies used multivariate analysis to adjust for 
potential confounders (9 adjusted for medications, 7 adjusted for cardiovascular disease and 8 
adjusted for heart rate). 
Table 3 shows the description of reference group, outcomes evaluated, timing of 
assessment and results.  The definition of PR prolongation varied across the studies from 
>200 ms to >220 ms and follow up for outcomes amongst studies was between 5 to 24 years.  
Seven studies used the 200 ms as the cutoff and were included in the 1°HB analysis. 
Risk of adverse outcomes with prolonged PR interval 
 The risk of mortality with prolonged PR interval is shown in Figure 2.  There were a 
total of seven studies in the analysis and five of which adjusted for potential confounders.  
The pooled estimate of adjusted studies (based on a total of 14,454 deaths /37,634 
participants) suggest a significant increase in mortality with prolonged PR interval (RR 1.24 
95% CI 1.02-1.51). The crude event rate for the two unadjusted studies were 547 
deaths/2,331 participants (38%) in the PR prolongation arm as compared to ?? in the control 
arm The pooled estimate from unadjusted analyses (that are at high risk of bias) showed that 
prolonged PR interval was associated with reduced overall mortality RR 0.73 (0.55 – 0.99).   
 The risk of other adverse outcomes with prolonged PR interval is shown in Figure 3.  
Prolonged PR interval was associated with significant risk of heart failure or left ventricular 
dysfunction (RR 1.39 95%CI 1.18-1.65, 3 studies, event rate 2,389/17,323, 14%) and atrial 
fibrillation (RR 1.45 95%CI 1.23-1.71, 8 studies, event rate 15,616/375,526, 4%) but not 
cardiovascular mortality, coronary heart disease or myocardial infarction or stroke or TIA. 
 Additional analysis was performed considering the all studies including patients with 
previous coronary heart disease and hypertension and adjustments for medication and 
cardiovascular disease (Table 4).  We observed similar significant increases in adjusted 
mortality, heart failure or LV dysfunction and atrial fibrillation in these additional analyses. 
 In addition, Cheng et al was the only study to report two important outcomes 
associated with 1°HB which were need for pacemaker insertion and progression of heart 
block. 
Risk of adverse outcomes with 1°HB heart block 
 The results for adverse outcomes with 1°HB are shown in Figure 4.  Similar to 
prolonged PR interval there were significant increases in mortality (RR 1.31 95% CI 1.18-
1.46), heart failure (RR 1.39 95% CI 1.18-1.65) and atrial fibrillation (RR 1.47 (1.18-1.83) 
but not cardiovascular mortality, coronary heart disease or stroke.
Discussion 
 Our results suggest that prolonged PR interval and 1°HB is not a benign condition and 
is associated with increased mortality, heart failure or left ventricular dysfunction and atrial 
fibrillation.  It is notable that there is a long follow up for many of these studies (up to 24 
years) and adjustments for potential confounders is an important consideration.  It appears 
that prolonged PR interval and 1°HB may be clinically relevant when found incidentally but 
the best management is unclear. 
 
 The mechanism of 1°HB and adverse cardiovascular outcomes and mortality is 
unclear.  Cheng et al suggest that chronic PR prolongation could be a precursor to more 
severe degrees of conduction block.[9]  This is supported by their findings that there was a 
significant increase in need for pacemaker and progression of heart block with 1°HB.[9].   
They also suggest that prolongation of PR interval may be a marker of other cardiovascular 
changes associated with worse prognosis such as advanced physiological age which may 
manifest as calcification or fibrosis of the cardiac skeleton.[9]  The age related changes is 
supported by electrophysiological studies which suggest that the atrial becomes more 
refractory and there is increased atrial conduction time.[24,25]  Age is known to be 
associated with increased risk of mortality and cardiovascular disease such as atrial 
fibrillation and heart failure.  We have observed evidence supporting this as the patients in 
the prolonged PR interval group were older patients in several studies [6, 9,10,14,17] so 
adjustments for the potential confounder age and age related comorbidity is an important 
statistical consideration.  It is likely that the increase risk of mortality may be related to 
develop of cardiovascular pathology such as atrial fibrillation, other arrhythmias and heart 
failure.  It is also possible that risk factors (eg. age) for heart block development are also 
shared risk factors for heart failure, atrial fibrillation and mortality. 
 We have shown that there is increased risk of both atrial fibrillation and heart failure 
with prolonged PR interval but whether the two are related is unclear.  It is known that 1°HB 
can manifest from structural heart disease as pathology of the conduction pathway, especially 
the right atrium.  Atrial fibrillation can occur commonly due to heart failure causing 
stretching of the myocardium and secondary changes to the right atrium.  However, 
prolongation of the PR interval may disrupt the normal cardiac filling pressures which may 
also exacerbate heart failure.[17]  Unfortunately the studies included were unable to 
determine the sequence of problems that develop after baseline 1°HB as it is not apparent if 
patients had arrhythmias or heart failure prior to mortality.  The study by Aro et al did report 
observation of a few cases of AF in subjects with long PR interval but higher AV block 
degree was not noted.[6]  More studies are needed to confirm these findings.  In addition, 
prolonged PR interval may unmask existing cardiac pathology such as heart failure.    
There are also a few reasons why prolonged PR interval may be associated with heart 
failure.  Crisel et al suggested that 1°HB may be a marker of diffuse ischaemic heart 
disease.[17]  However, our findings do not support this as prolonged PR interval does not 
increase coronary heart disease, stroke and cardiovascular mortality which are related to 
atherosclerosis and vascular pathology.  Magnani et al suggest that prolongation of PR has 
been associated with obesity, waist circumference and components of metabolic syndrome 
which are also associated with incident heart failure.[21]  They also suggest that hypertension 
may be a confounder that causes heart failure with both preserved and compromised systolic 
function and cause elevated intracardiac pressures and secondary altered atrial electrical 
function.[21] 
 
 Our results support and differ from the findings of existing studies.  Cheng et al 
conducted a meta-analysis of six cohort studies and reported an increased risk of atrial 
fibrillation with 1°HB.  Two additional studies in our review Perez et al[11] and Uhm et 
al[13] and both of these studies suggest an increased risk of atrial fibrillation with 1°HB.  We 
build upon this review by including the other outcomes mortality, cardiovascular mortality, 
heart failure, coronary heart disease and stroke.  Our findings differ from those of the study 
Aro et al which suggest no increase in mortality or atrial fibrillation, heart failure or stroke in 
a middle-aged general population.[6]  One possible explanation for the difference in the 
findings is that for this study there was a much higher event rate compared to the average 
among the studies (mortality 56% vs 38%, heart failure 16% vs 14%, atrial fibrillation 15% 
vs 4%).  This study made an interesting finding that many patients with 1°HB seem to revert 
back to normal PR interval. 
 The long follow up in many of these studies is an important consideration in the 
interpretation of the findings.  This may suggest that event rates may be very low so a long 
follow up time is need to capture enough events to show a difference.  The benign nature of 
1°HB is notable because it is not clear how long patients have had heart block for prior to 
inclusion in the study.  This represents a problem because all of the studies are observational 
in nature.  However, the long follow up time between heart block and adverse events may 
provide a window for which patients can be identified and management can be implemented 
to reduce risk of cardiovascular pathology.   
 An important question generated from these findings is what should be done if 1°HB 
is incidentally found.  Guidelines recommend against pacemaker insertion unless patients are 
symptomatic and according to ESC guidelines the PR interval is >300 ms.[7,8]  The options 
include following up these patients and if so how frequently (probably unrealistic to see them 
yearly, perhaps every 3 years or 5 years).  It is also not clear what should be done for these 
patients perhaps some sort of cardiovascular risk assessment with prognostic scores. It may 
also be a chance to encourage a healthier lifestyle like quitting smoking, eating a healthier 
diet, lose weight and increase physical activity.  
 Our studies have a number of strengths and limitations.  We included over 400,000 
subjects from 12 studies.  We were able to consider the effects of adjustments including the 
impact of adjustments for medications and cardiovascular disease.  Furthermore, we 
evaluated a variety of clinically relevant cardiovascular outcomes.  All of the included studies 
are all observational in nature.  For some cardiovascular event follow up the outcome 
ascertainment is less reliable but for mortality events are easily ascertained.  This is a 
problem for outcomes that may be asymptomatic such as atrial fibrillation especially in 
studies which use hospitalization data.  We also observed either a lack of description of the 
leads use for evaluation of PR interval or inconsistencies in choice of leads for evaluation for 
heart block among the included studies.    We were also unable to determine if prolongation 
of PR interval was persistent among the studies. 
In conclusion, there is growing evidence that prolonged PR interval and 1°HB is not a 
benign condition and patients with this condition are at increased risk of mortality, heart 
failure or left ventricular dysfunction and atrial fibrillation.  Future studies should focus on 
providing mechanistic insight and define the optimal monitoring strategy for such patients. 
Table 1: Study design and participant characteristics 
Study ID Study design; year; country No. of 
participants 
Mean age % Male Participant inclusion criteria 
Aro 2014 Prospective cohort study; 1966 to 
2007; Finland. 
10,785 44 years. 52% Participants were ‘apparently healthy’ community 
population, aged 30-59 years between 1966 and 1972 in the 
Finnish Social Insurance Institution's Coronary Heart 
Disease Study. 
Cheng 2009 Prospective cohort study; 1968 to 
2007; USA. 
7,575 47 years. 46% Participants were community-based individuals from the 
Framingham Heart Study. 
Crisel 2011 Prospective cohort study; 
enrolment 2000 to 2002; USA. 
938 66 years. 82% Participants had stable coronary artery disease in the Heart 
and Soul Study. 
Erikssen 1984 Prospective cohort study; 
enrolment 1972-1975; Norway. 
1,635  40-59 years 
at baseline. 
100% Participants were ‘apparently healthy’ men aged 40-59 
years free of coronary heart disease. 
Hisamatsu 
2015 
Prospective cohort study; 1980 to 
2009; Japan. 
9,051 50 years. 44% Participants were community dwellers, aged 30-95 years 
from 300 randomly selected areas throughout Japan. 
Knuiman 
2014 
Prospective cohort study; 1994 to 
2010; Australia. 
4,267 52 years. 44% Participants were community-based adults, age 25-84 years 
in the Busselton Health Study. 
Kobayashi 
2014 
Prospective cohort study; 
baseline survey 1989 to 1994; 
Japan. 
5,425 30-83 
years. 
47%. Participants were Japanese urban adults age 30-83 years 
without prior cardiovascular disease who attended a routine 
examination. 
Magnani 2013 Prospective cohort study; 1997 to 
2011; USA. 
2,722 74 years. 48%. Participants were a random sampling of community-
dwelling older patients (age 70-79 years) free of disability 
or functional limitation from the Health, Aging and Body 
Composition Study. 
Nielsen 2013 Prospective cohort study; 2001 to 
2010; Denmark. 
288,181 Median 54 
years. 
45%. Participants were from primary care who had ≥1 ECG 
recorded at the Copenhagen General Practitioners' 
Laboratory. 
Perez 2009 Retrospective cohort study; Mar 
1987 to Jul 2000; USA. 
42,751 56 years. 90%. Participants had initial ECG between Mar 1987 and Jul 
2000. Indications for ECG and background disease – not 
known, but patients with known AF were excluded from 
study. 
Rajala 1985 Prospective cohort study; Jan 
1977 to Dec 1982; Finland. 
674 Age >85 
years. 
18%. Participants were 85 years or older community-based 
sample living in the city of Tampere in 1977. 
Soliman 2009 Retrospective cohort study; 1987 
to 1998; USA. 
15,429 54.2 years. 45%. Participants were from 4 US communities aged 45 to 64 
years in the Atherosclerosis Risk in Communities study. 
Soliman 2014 Prospective cohort study; 1988 to 
Dec 2006; USA. 
7,501 59.3 years. 47%. Participants were civilian noninstitutionalized US 
population in the NHANES study. 
Uhm 2013 Retrospective cohort study; 
Unclear; Korea.  
3,816 61.0 years. 47.2%. Participants were age >18 years with hypertension and sinus 
rhythm on first ECG. 
 
Table 2: Study quality assessment 
Study ID Definition and 
Ascertainment of 
PR prolongation 
Method of Ascertainment of 
outcome  
Lost to follow up Adjustment for potential confounders 
Medications Cardiovascular 
disease or risk factors 
Other 
Aro 2014 12-lead ECG at 
baseline 
containing average 
7 to 8 beats. PR 
prolongation was 
>200 ms. PR 
interval defined 
from onset of P-
wave to end of PR 
segment measured 
from the bipolar 
limb lead in which 
the interval was 
longest.   
Mortality data from Causes of 
Death Register and other 
outcomes from hospitalization 
records from the Finnish 
Hospital Discharge Register. 
<2% lost from 
moving abroad. 95 
participants were 
excluded for missing 
or unreadable ECG 
or previous AF or 
unreadable PR 
interval. 
Chronotropic 
medications. 
Cardiovascular 
disease. 
Age, sex, BMI, heart 
rate. 
Cheng 2009 Baseline 12 lead 
ECG.  A single 
lead II was used 
with 2 
measurements 
using digital 
calipers and PR 
interval defined by 
interval from onset 
of P wave to end 
of PR segment. PR 
prolongation 
defined by >200 
ms. 
Patients underwent 
surveillance for death and 
cardiovascular events and AF 
and pacemaker implantation 
was ascertained by a review of 
medical histories, physical 
examinations, hospitalization 
and patient records. A panel of 
3 experienced investigators 
reviewed pertinent medical 
records for all suspected new 
events. 
146 participants were 
excluded for 
inadequate 
measurement of PR 
interval and missing 
covariate data. 
Exclusion of nodal-
blocking medications. 
Stratified by 
cardiovascular status. 
Adjusted for age, heart 
rate, body mass index, 
hypertension, smoking, 
diabetes and total:HDL 
cholesterol levels.  Also 
adjusted for atrial 
premature beats, valve 
disease, ECG left 
ventricular hypertrophy 
and QRS interval. 
Crisel 2011 12 lead ECG at 
enrolment. 
Prolonged PR 
interval defined by 
≥220 ms.  Unclear 
which lead for 
Annual telephone interviews or 
proxies regarding recent 
emergency room visits, 
hospitalizations or death.  Two 
independent blinded 
adjudicator reviewed medical 
86 participants were 
excluded due to lack 
of ECG or advanced 
AV block. 
Beta-blocker use, 
digoxin use. 
Heart failure. Age, gender, ethnicity, 
resting heart rate, QRS 
duration >100 ms, 
inducible ischemia, LV 
ejection fraction, 
diastolic dysfunction, 
measurement. records, death certificate and 
coroner's reports. 
arrhythmia or 
pacemaker. 
Erikssen 1984 12 lead ECG. PR 
taken by mean of 
5 consecutive 
beats in lead with 
longest PR 
interval.  PR 
prolongation 
defined by >210 
ms.   
Detailed criteria for diagnosis 
is reported elsewhere  Erikssen 
and Mundal 1982. 
182 participants were 
excluded. 
None. None. None. 
Hisamatsu 
2015 
Baseline ECG. PR 
prolongation 
defined by ≥220 
ms. Unclear lead 
for PR evaluation. 
Study participants observed 
from baseline ECG to death, 
censor or end of follow up by 
unclear method. 
Unclear number of 
exclusions. 
Antihypertensive 
medications. 
None. Age, sex, body mass 
index, systolic blood 
pressure, total 
cholesterol, diabetes 
mellitus, smoking status, 
drinking status, heart 
rate, LVH on ECG, 
suspected CHD on ECG. 
Knuiman 2014 12-lead ECG. 
Unclear definition 
for long PR and 
unclear lead for 
PR evaluation. 
AF from hospital admission 
with primary or other diagnosis 
of atrial fibrillation/flutter and 
no prosthetic heart valve or 
coronary artery bypass 
procedure or ECG codes. 
Unclear. Hypertension 
treatment. 
None. Sex, age, height, body 
mass index. 
Kobayashi 
2014 
Baseline 12-lead 
ECG. PR 
prolongation 
defined by ≥220 
ms.  Unclear lead 
for PR evaluation. 
Unclear. Unclear. None. None. Age, sex, body mass 
index, hypertension, 
hypercholesterolemia, 
diabetes, current 
smoking, current alcohol 
drinking and estimated 
glomerular filtration rate. 
Magnani 2013 Baseline ECG.  
PR interval 
defined by lead II 
using average 
measure of 3 
consecutive beats 
Follow up with annual 
examinations and 12 month 
telephone contact and records 
from hospitalizations were 
reviewed.  Incident AF from 
linking ICD codes and 
81 had missing ECG 
data or PR interval. 
Amiodarone, cardiac 
glycosides, calcium 
channel blockers, 
beta-blockers. 
Prevalent 
cardiovascular 
disease. 
Age, sex, site, body mass 
index, heart rate, systolic 
and diastolic blood 
pressure, past/current 
smoking, ratio of 
Total/HDL cholesterol, 
or 2 at slower 
heart rates. PR 
prolongation 
defined by >200 
ms. 
mortality from participant 
proxy or other participant 
representative, hospital 
records, obituary or search of 
National Death Index. 
electrocardiographic 
LVH. 
Nielsen 2013 ECG digitally 
recorded and 
stored 
electronically. PR 
interval from 
median beat using 
information from 
all 12 leads.  PR 
prolongation ≥196 
ms for women and 
≥204 ms for men. 
Follow up data from Danish 
registry with hospital, 
ambulatory or emergency 
room discharge diagnosis of 
atrial fibrillation or flutter. 
17,708 ECG not 
consistent with 
measured PR 
interval. 
AV nodal-blocking 
medications (beta-
blockers or calcium 
antagonist). 
Heart failure, 
myocardial 
infarction, valvular 
heart disease. 
Gender, hypertension, 
diabetes, 
hyperthyroidism, heart 
rate, QT interval, left 
ventricular hypertrophy. 
Perez 2009 ECG with 
computer 
measurements of 
PR interval. 
Unclear lead for 
evaluation and PR 
prolongation 
defined by >200 
ms. 
Follow up ECG and death 
from Veterans Affairs Health 
Care System electronic 
medical records. 
Unclear. None. None. Age, sex, premature 
atrial contraction, 
abnormal P axis, Pmax 
>120 ms, Pindex >35 ms, 
left atrial enlargement, 
premature ventricular 
complex, left bundle 
branch block, left 
ventricular hypertrophy. 
Rajala 1985 12-lead ECG. First 
degree heart block 
with ≥220 ms in 
any leads I, II, III, 
aVL or aVF.  
Follow up for survival but 
unclear how. 
Unclear. None. None. None. 
Soliman 2009 ECG at baseline 
with PR duration 
defined by mean P 
wave duration plus 
the mean PR 
segment duration 
in 12-lead ECG. 
PR prolongation 
Annual phone contact, hospital 
cardiovascular disease 
discharges and diagnoses were 
adjudicated. 
363 with poor quality 
baseline ECG 
recording, baseline 
ECG condition 
affecting quality of P 
wave measurement or 
ethnicity other than 
black or white were 
None. None. Age, sex, ethnicity, 
hypertension, systolic 
blood pressure, diabetes, 
blood lipids, smoking 
status, body mass index. 
defined by upper 
5th centile and 1 
increase in 
standard deviation. 
excluded. 
Soliman 2014 12-lead ECG at 
baseline with PR 
interval defined in 
lead II.  PR 
prolongation 
defined by >200 
ms. 
Follow up mortality by 
probabilistic matching with 
National Death Index. 
Unclear. Use of antiarrhythmic 
or AV nodal blocking 
drugs. 
Prior cardiovascular 
disease. 
Age, sex, race/ethnicity, 
heart rate, smoking 
status, systolic blood 
pressure, diabetes, 
total/HDL cholesterol 
ratio and BMI. 
Uhm 2013 Medical records of 
all ECG.  PR 
prolongation 
defined by >200 
ms. Unclear lead 
for PR evaluation. 
Review of medical records and 
ECG. 
Unclear. Use of 
nondihydropyridine 
calcium channel 
blockers. 
History of myocardial 
infarction. 
Age, sex, heart rate, QRS 
duration, left ventricular 
hypertrophy on ECG. 
Table 3: Outcomes evaluated and results 
Study ID Description of reference 
group (e.g. PR interval less  
than 200 ms or PR interval 
in normal range 120-200 
ms, 80-200 ms, other) 
Outcomes evaluated and timing of 
assessment 
Results 
Aro 2014 ≤200 ms Follow up for 30 years. Multivariate adjusted HR: 
All-cause mortality: 140/222 vs 5,933/10,563, HR 1.05 (0.89-1.24). 
Cardiovascular mortality: 44/222 vs 1,904/10,563, HR 0.94 (0.70-1.27). 
Heart failure: 42/222 vs 1,673/10,563, HR 1.22 (0.90-1.65). 
Coronary artery disease: 74/222 vs 3,465/10,563, HR 0.97 (0.77-1.22). 
Atrial fibrillation: 35/222 vs 1,591/10,563, HR 1.03 (0.74-1.45). 
TIA or stroke: 50/222 vs 1,877/10,563, HR 1.23 (0.92-1.62). 
Cheng 2009 ≤200 ms Up to 35 years. Atrial fibrillation: 25/124 vs 456/7,451, multivariate HR 2.36 (1.53-
3.64). 
Pacemaker insertion: 26/124 vs 98/7,451, multivariate HR 4.32 (2.46-
7.59). 
All-cause mortality: 62/124 vs 1,677/7,451, multivariate HR 1.48 (1.10-
1.99). 
Crisel 2011 <220 ms Up to 5 years. Heart failure: 26/87 vs 97/851, adjusted for medications HR 2.33 (1.49-
3.65). 
Cardiovascular mortality: 15/87 vs 52/851, adjusted for medications HR 
2.33 (1.28-4.22). 
All-cause mortality: 42/87 vs 243/851, adjusted for medications HR 1.58 
(1.13-2.20). 
Heart failure or cardiovascular mortality: 34/87 vs 122/851, adjusted for 
medications HR 2.43 (1.64-3.61). 
Heart failure: 26/87 vs 97/851, adjusted for heart failure  HR 2.02 (1.24-
3.31). 
Cardiovascular mortality: 15/87 vs 52/851, adjusted for heart failure HR 
2.29 (1.18-4.45). 
All-cause mortality: 42/87 vs 243/851, adjusted for heart failure HR 1.49 
(1.04-2.14). 
Heart failure or cardiovascular mortality: 34/87 vs 122/851, adjusted for 
heart failure HR 2.09 (1.36-3.23). 
Erikssen 1984 ≤210 ms Myocardial infarction, angina 
pectoris, pathological exercise 
ECG, death from CHD, total 
CHD events. 
Myocardial infarction: 6/98 vs 54/1,537. 
Angina pectoris: 3/98 vs 76/1,537. 
Pathological exercise ECG: 7/98 vs 205/1,537. 
Death from CHD: 1/98 vs 36/1,537. 
Total deaths: 3/98 vs 71/1,537. 
Hisamatsu 
2015 
<220 ms All cause mortality, 
cardiovascular disease mortality, 
coronary heart disease mortality, 
stroke mortality with mean follow 
up of 24.3 years. 
All cause mortality: total events 3,269/9,051, multivariate HR 1.06 (0.85-
1.31). 
Cardiovascular disease mortality: total events 1,101/9,051, multivariate 
HR 0.94 (0.65-1.37). 
Coronary heart disease mortality: total events 227/9,051, multivariate HR 
1.49 (0.76-2.92). 
Stroke mortality: total events 491/9,051, multivariate HR 0.70 (0.37-
1.31). 
Knuiman 
2014 
Unclear, not long PR 
interval. 
Incident atrial fibrillation at 
follow up of 15 years. 
Incident atrial fibrillation: total events 343/4,267, multivariate HR 1.29 
(0.68-2.44). 
Kobayashi 
2014 
<220 ms Cardiovascular disease, coronary 
heart disease and stroke at 13.1 
years follow up. 
All cardiovascular disease: total events 421/5,425, multivariate HR 2.98 
(1.22-7.31). 
Coronary heart disease: total events 180/5,425, multivariate HR 1.57 
(0.22-11.42). 
Stroke: total events 241/5,425, multivariate HR 3.90 (1.42-10.72). 
Cerebral infarction: total events 144/5,425, multivariate HR 2.98 (1.22-
7.31). 
Magnani 2013 ≤200 ms Incident heart failure, atrial 
fibrillation and all-cause 
mortality. 
Incident heart failure: total events 369/2,722, multivariate HR 1.46 (1.11-
1.93) 
Incident atrial fibrillation: total events 537/2,722, multivariate HR 1.26 
(0.99-1.61) 
All-cause mortality: total events 832/2,722, multivariate HR 1.14 (0.94-
1.39). 
Nielsen 2013 <200 ms. Atrial fibrillation at median 
follow up of 5.7 years. 
Incident atrial fibrillation: total events 11,087/288,181, multivariate HR 
1.26 (1.17-1.35) (reference group PR interval 150-161 ms). 
Men multivariate HR 1.18 (1.06-1.30) and women multivariate HR 1.30 
(1.17-1.44).  
Perez 2009 ≤200 ms Incident atrial fibrillation at 5.3 
years. 
Risk of AF with PR >200 ms: total events 1,050/42,751, multivariate HR 
1.3 (1.1-1.6). 
Rajala 1985 <220 ms Mortality at 5 years follow up. Crude 5 year mortality: first degree heart block 20/39 vs normal 453/657. 
 Soliman 2009 1SD change and upper 5th 
centile vs 95th centile of 
PR duration. 
Incident atrial fibrillation and 
ischemic stroke with follow up of 
6.97 years. 
Total AF events 117/15,429. Total ischemic stroke events 599/15,429. 
Risk of ischemic stroke with 1 SD change in PR duration: multivariate 
HR 1.00 (0.92-1.08).  
Risk of AF with 1 SD change in PR duration: multivariate HR 1.41 
(1.20-1.65). 
Risk of AF with upper 5th centile vs 95th centile of PR duration: 
multivariate HR 1.59 (0.77-3.30). 
Soliman 2014 ≤200 ms for crude analysis 
but adjusted analysis 120-
200 ms. 
Mortality at median follow-up of 
13.8 years. 
Prolonged PR interval and mortality: 325/654 vs 2,216/6,847. 
High-P duration prolong PR interval and mortality: multivariate HR 2.00 
(1.34-2.99). 
Low-P duration prolong PR interval and mortality: multivariate HR 0.99 
(0.86-1.14). 
Uhm 2013 ≤200 ms Advanced AV block, sick sinus 
syndrome, atrial fibrillation, LV 
dysfunctions follow up period of 
9.4 years. 
First degree heart block and multivariate outcomes: 
Advanced AV block: 12/544 vs 26/3,272, HR 2.77 (1.38-5.59).  
Sick sinus syndrome: 8/544 vs 277/3,272, HR 1.32 (0.61-2.84).  
Atrial fibrillation: 98/544 vs 277/3,272, HR 2.33 (1.84-2.94).  
LV dysfunction: 59/544 vs 245/3,272, HR 1.49 (1.11-2.00).  
 
Table 4: Summary of meta-analysis results 
A) General population studies 
Adverse outcome General population studies 
No. of 
studies 
Events/Total Risk ratio (95% CI) 
All mortality 
Adjusted only 
Unadjusted only 
 
5 
2 
 
14,454/37,634 
15,001/39,965 
 
1.24 (1.02-1.51) 
0.73 (0.55-0.99) 
Cardiovascular mortality 3 3,086/21,471 0.93  (0.74-1.17) 
Heart failure or LV 
dysfunction 
3 2,389/17,323 1.39 (1.18-1.65) 
CHD or MI 4 4,006/26,896 1.08 (0.85-1.36) 
Atrial fibrillation 8 15,616/37,526 1.45 (1.23-1.71) 
Stroke or TIA 4  1.13 (0.82-1.56) 
B) All studies (including studies of patients with CAD) 
Adverse outcome All studies (including studies of patients with CAD) 
No. of 
studies 
Events/Total Risk ratio (95% CI) 
All mortality 
Adjusted only 
Unadjusted only 
 
7 
2 
 
14,739/38,572 
547/2,331 
 
1.23 (1.01-1.49) 
0.73 (0.55-0.99) 
Cardiovascular mortality 4 3,153/22,409 1.14 (0.73-1.76) 
Heart failure or LV 
dysfunction 
4 2,512/18,261 1.51 (1.22-1.88) 
CHD or MI 4 4,006/26,896 1.08 (0.85-1.36) 
Atrial fibrillation 8 15,616/375,526 1.45 (1.23-1.71) 
Stroke or TIA 4 3,258/40,690 1.13 (0.82-1.56) 
C) Only inclusion of studies that adjusted for medications 
Adverse outcome Only inclusion of studies that adjusted for medications 
No. of 
studies 
Events/Total Risk ratio (95% CI) 
All mortality 
Adjusted only 
 
7 
 
14,739/48,209 
 
1.23 (1.01-1.49) 
Cardiovascular mortality 3 3,116/20,774 1.19 (0.75-1.88) 
Heart failure or LV 
dysfunction 
4 2,512/18,261 1.51 (1.22-1.88) 
CHD or MI 1 3,539/10,785 0.97 (0.77-1.22) 
Atrial fibrillation 6 14,449/317,346 1.50 (1.15-1.96) 
Stroke or TIA 2 2,418/19,836 1.00 (0.59-1.70) 
D) Only inclusion of studies that adjusted for CVD 
Adverse outcome Only inclusion of studies that adjusted for CVD 
No. of 
studies 
Events/Total Risk ratio (95% CI) 
All mortality 
Adjusted only 
 
6 
 
11,470/39,158 
 
1.26 (1.02-1.56) 
Cardiovascular mortality 2 2,015/11,723 1.42 (0.59-3.46) 
Heart failure or LV 
dysfunction 
4 2,512/18,261 1.51 (1.22-1.88) 
CHD or MI 1 3,539/10,785 0.97 (0.77-1.22) 
Atrial fibrillation 5 14,106/313,079 1.53 (1.14-2.04) 
Stroke or TIA 1 1,927/10,785 1.23 (0.93-1.63) 
CAD=coronary artery disease, CVD=cardiovascular disease, CHD=coronary heart disease, 
MI=myocardial infarction, TIA=transient ischemic attack 
Figure 1: Process of study selection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
   
 
 
 
 
 
  
 
879 studies from MEDLINE and EMBASE search using terms: 
(first degree heart block or prolonged PR interval or PR 
prolongation or first-degree atrioventricular block) AND (atrial 
fibrillation or myocardial infarction or acute coronary syndrome 
or ischemic heart disease or ischaemic heart disease or coronary 
heart disease or coronary artery disease or stroke or 
cerebrovascular disease or cerebrovascular accident or heart 
failure or cardiac failure or mortality or death). 
 
23 potentially relevant studies after 
review of full manuscripts. 
 
14 included studies: 12 general 
population cohorts, 1 coronary heart 
disease cohorts and 1 hypertensive 
cohort. 
 
9 studies excluded from meta-
analysis but described in Appendix: 
1 aortic stenosis cohort, 1 
angiography cohort, 1 primary 
angioplasty cohort, 1 sinus nodal 
dysfunction cohort, 3 catheter 
ablation cohorts, 1 cohort of heart 
failure and 1 cohort of cardiac 
resynchronization therapy. 
 
41 potentially relevant studies after 
review of titles and abstracts. 
 
838 studies clearly did not meet 
inclusion criteria. 
18 studies excluded: 6 studies lacked 
outcomes, 1 editorial, 4 
letters/comments, 6 reviews, 1 case 
report.  
Figure 2: Risk of mortality with prolonged PR interval 
 
Figure 3: Risk of adverse outcomes with prolonged PR interval 
 
 
 
Figure 4: Risk of adverse outcomes with first-degree heart block 
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Appendix 1: Excluded studies 
Study ID No. of 
Participants 
Population Outcomes evaluated 
Bang 
2014 
1,421 Mild-moderate aortic 
stenosis 
Atrial fibrillation, heart failure, aortic valve replacement 
Gomez-
Talavera 
2014 
913 Primary angioplasty 
cohort 
Death, re-infarction, death/recurrent infarction 
Holmqvist 
2014a 
9,637 Coronary 
angiography cohort 
Death, sudden cardiac death, death or stroke, CV death or 
hospitalization. 
Holmqvist 
2014b 
2,010 Sinus nodal 
dysfunction 
Death/stroke, death/stroke/heart failure, heart failure, 
death, cardiovascular death, atrial fibrillation 
Lee 2012 351 Cardiac 
resynchronization 
therapy 
Mortality 
Ozcan 
2014 
1,573 Patients with SVT 
with catheter ablation 
Atrial fibrillation 
Park 
2014a 
576 Patients with catheter 
ablation 
Atrial fibrillation 
Park 
2014b 
1,986 Heart failure Death 
Wu 2014 224 Atrial fibrillation 
with catheter ablation 
Atrial fibrillation recurrence 
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